Perspectives on population-based prostate cancer screening
Abstract
Prostate cancer is one of the key causes of high cancer mortality in Russia and the world.
In the absence of effective preventive measures, population-based screening using prostate-specific antigen (PSA) may be promising for mortality reduction. Despite conflicting results of randomized trials, the efficacy of prostate cancer screening in mortality reduction may be up to 30%. Overdiagnosis, typical for prostate cancer screening, limits a population-based implementation. Possible methods to decrease the amount of overdiagnosis and increase the effectiveness of population-based prostate cancer screening are discussed in a brief review of the literature. An analysis of selected results of randomized trials and a design for a new randomized trial are presented.
Downloads
References
Andriole G.L., E.D Crawford, R.L Grubb, S.S. Buys, D. Chia, T.R. Church et al. (2009). Mortality results from a randomized prostate-cancer screening trial // New England journal of medicine. 360(13): 1310–1319.
Auvinen A., A. Rannikko, K. Taari, P. Kujala, T. Mirtti, A. Kenttämies et al. (2017). A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale // European journal of epidemiology. 32(6): 521–527.
De Carvalho T.M., E.A. Heijnsdijk, H.J. de Koning (2017). Estimating the risks and benefits of active surveillance protocols for prostate cancer: a microsimulation study // BJU international. 119(4): 560–566.
De Koning H.J., R. Meza, S.K. Plevritis, K. ten Haaf, V.N. Munshi, J. Jeon et al. (2014). Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force // Annals of internal medicine. 160(5): 311–320.
Elwood M. (2004). A misleading paper on prostate cancer screening // The prostate. 61(4): 372–372.
Evans I., H. Thornton, I. Chalmers, P. Glasziou (2011). Testing treatments: better research for better healthcare. 2nd edition. London: Pinter & Martin. 34 p.
Ford I., J. Norrie (2016). Pragmatic Trials // New England journal of medicine. 375(5): 454–463.
Heijnsdijk E.A.M., T.M. de Carvalho, A. Auvinen, M. Zappa, V. Nelen, M. Kwiatkowski et al. (2015). Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data // Journal of the National cancer institute. 107(1): 366.
Labrie F., B. Candas, L. Cusan, J.L. Gomez, A. Bélanger, G. Brousseau et al. (2004). Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial // The prostate. 59(3): 311–318.
Loeb S., M.A. Bjurlin, J. Nicholson, T.L. Tammela, D.F. Penson, H.B. Carter et al. (2014). Overdiagnosis and overtreatment of prostate cancer // European urology. 65(6): 1046–1055.
Pinsky P.F., A. Black, B.S. Kramer, A. Miller, P.C. Prorok, C. Berg (2010). Assessing contamination and compliance in the prostate component of the Prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial // Clinical trials. 7(4): 303–311.
Roobol M.J., M. Kerkhof, F.H. Schröder, J. Cuzick, P. Sasieni, M. Hakama et al. (2009). Prostate cancer mortality reduction by prostate-specific antigen–based screening adjusted for nonattendance and contamination in the European randomised study of screening for prostate cancer (ERSPC) // European urology. 56(4): 584–591.
Schröder F.H., J. Hugosson, M.J. Roobol, T.L.J. Tammela, S. Ciatto, V. Nelen et al. (2009). Screening and prostate-cancer mortality in a randomized European study // New England journal of medicine. 360(13): 1320–1328.
Tsodikov A., R. Gulati, E.A.M. Heijnsdijk, P.F. Pinsky, S.M. Moss, S. Qiu et al. (2017). Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials // Annals of internal medicine. 167(7): 449-455.
